Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers.

Zhu, Min; Gosselin, Nathalie H; Kuchimanchi, Mita; Johnson, Jessica; McCaffery, Ian; Mouksassi, Mohamad-Samer; Loh, Elwyn; Lu, Jian-Feng

Zhu, Min; Gosselin, Nathalie H; Kuchimanchi, Mita; Johnson, Jessica; McCaffery, Ian; Mouksassi, Mohamad-Samer; Loh, Elwyn; Lu, Jian-Feng.

Afiliación

Zhu M; Amgen Inc., Thousand Oaks, CA, USA.
Gosselin NH; Pharsight-A Certara Company, Montreal, QC, Canada.
Kuchimanchi M; Amgen Inc., Thousand Oaks, CA, USA.
Johnson J; Amgen Inc., Thousand Oaks, CA, USA.
McCaffery I; Amgen Inc., Thousand Oaks, CA, USA.
Mouksassi MS; Pharsight-A Certara Company, Montreal, QC, Canada.
Loh E; Amgen Inc., Thousand Oaks, CA, USA.
Lu JF; Amgen Inc., Thousand Oaks, CA, USA.

Clin Pharmacol Drug Dev ; 2(4): 367-78, 2013 Oct.

Article en En | MEDLINE | ID: mdl-27121941

Palabras clave

IGF1R; ganitumab (AMG 479); monoclonal antibody; pancreatic cancer; pharmacokinetics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google